Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 409

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 409
---
 Company registered for sale from time to time in one or more offerings an unlimited amount of any combination of the Company’s common stock, preferred stock, debt securities and warrants, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. This automatic shelf registration statement will remain in effect for up to three years from the date it became effective. As of September 30, 2025, the Company had not issued any securities pursuant to the automatic shelf registration statement.On November 2, 2023, the Company entered into a Sales Agreement (the “2023 Sales Agreement”) with Leerink and Cantor Fitzgerald & Co. (the “Sales Agents”), pursuant to which the Company may, from time to time, sell up to an aggregate amount of $200.0 million of its common stock through the Sales Agents in an “at-the-market” offering (the “ATM Offering”). The Company is not required to sell shares under the 2023 Sales Agreement. Sales of the Company’s common stock, if any, under the 2023 Sales Agreement may be made in any transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act. The Company will pay a given designated Sales Agent a commission of up to 3.0% of the aggregate gross proceeds of any shares of common stock sold through such Sales Agent pursuant to the 2023 Sales Agreement. As of September 30, 2025, the Company had not issued any securities pursuant to the 2023 Sales Agreement.

18

Common Stock Reserved for IssuanceCommon stock reserved for issuance is as follows:  As of September 30,2025Stock options, restricted stock units and performance stock units issued and outstanding11,183,252Reserved for future stock awards or option grants3,804,599Reserved for employee stock purchase plan1,806,244Common stock issuable upon conversion of convertible notes9,963,711 26,757,806

11. Stock-Based Compensation

Stock OptionsThe following table summarizes stock option activity during the nine months ended September 30, 2025 (in thousands, except share and per share data):  Number ofAwards Weighted-AverageExercisePriceWeighted-AverageRemainingContractualLife(in Years)AggregateIntrinsicValueOutstanding as of December 31, 2024 10,031,486$18.12 6.5$233,161 Granted1,740,525